|
|
|
| Relationship between RDW/ESR, Chemerin, IL-13 and Coronary Artery Dilatation in Acute Kawasaki Disease |
| LI Na, HAN Min |
| Xianyang Women and Children Hospital,Xianyang Shaanxi 712000 |
|
|
|
|
Abstract 【Objective】 To investigate the relationship between the level of red blood cells distribution width/erythrocyte sedimentation rate (RDW/ESR), Chemerin , interleukin-13 (IL-13) and coronary dilatation in acute Kawasaki disease.【Methods】A total of 135 children with acute Kawasaki disease treated in our hospital from August 2016 to August 2020 were selected and divided into dilation group (n=28) and non dilation group (n=107) according to whether coronary artery dilation occurred. The baseline data and RDW/ESR, Chemerin and IL-13 of the two groups were compared. The multivariate logistic regression equation was used to analyze the relevant influencing factors of coronary artery dilatation, and the levels of RDW/ESR, Chemerin and IL-13 of children with different therapeutic responsiveness to intravenous immunoglobulin were compared. The receiver operating characteristic curve (ROC curve) was used to analyze the value of each index and combined prediction of therapeutic responsiveness.【Results】RDW/ESR, Chemerin and IL-13 in the expansion group were higher than those in the non expansion group (P<0.05); Multiple logistic regression analysis showed that RDW/ESR, Chemerin and IL-13 were all related to coronary dilatation (P<0.05). The levels of Chemerin and IL-13 in treatment sensitive children were lower than those in non sensitive children (P<0.05). ROC curve showed that the AUC of the combination of Chemerin and IL-13 in predicting IVIG treatment response was higher than that predicted alone, and the AUC was 0.891.【Conclusion】RDW/ESR, Chemerin and IL-13 are all related to coronary artery dilatation in children with acute Kawasaki disease. Chemerin and IL-13 can effectively predict the therapeutic response of intravenous immunoglobulin, and provide basis for timely and effective individualized treatment.
|
|
Received: 19 April 2021
|
|
|
|
|
|
[1] MCCRINDLE B W,ROWLEY A H,NEWBURGER J W,et al. Diagnosis,treatment,and long-term management of Kawasaki disease:a scientific statement for health professionals from the American Heart Association[J].Circulation,2017,135(17):e927-e999.
[2] 李菲,周娟,丁媛,等.单中心6年川崎病住院患儿早期并发冠状动脉瘤危险因素分析[J].中华实用儿科临床杂志,2019,34(9):680-683.
[3] 孙乐,于宪一.川崎病冠状动脉病变危险因素及其预测[J].中国实用儿科杂志,2017,32(8):575-579.
[4] 文一州,王献民,郭永宏,等.基于Z值的川崎病并发冠状动脉损伤危险因素分析[J].重庆医学,2019,48(9):1579-1582.
[5] AYUSAWA M,SONOBE T,UEMURA S,et al.Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)[J].Pediatr Int,2005,47(2):232-234.
[6] 中华医学会儿科学分会心血管学组,中华医学会儿科学分会免疫学组,中华儿科杂志编辑委员会.川崎病冠状动脉病变的临床处理建议[J].中华儿科杂志,2012,50(10):746-749.
[7] 陈杰,周玉杰,赵梦华,等.实验室指标在不完全型川崎病冠状动脉损伤中的临床价值[J].检验医学,2019,34(11):998-1001.
[8] BERDEJ-SZCZOT E,MAĿECKA-TENDERA E,GAWLIK T,et al. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease[J].Kardiol Pol,2017,75(3):261-266.
[9] 王策,于宪一.婴儿川崎病的临床特点以及冠状动脉损伤危险因素分析[J].中国小儿急救医学,2019,26(11):836-839.
[10] SZYGULA-JURKIEWICZ B,SZCZUREK W,SKRZYPEK M,et al. Red blood cell distribution width in end-stage heart failure patients is independently associated with all-cause mortality after orthotopic heart transplantation[J].Transplant Proc,2018,50(7):2095-2099.
[11] 程小兵,陈燕,罗娟娟,等.冠心病患者高密度脂蛋白胆固醇与红细胞分布宽度的相关性研究[J].临床心血管病杂志,2019,35(7):616-619.
[12] 朱再富,范晓晨.川崎病患儿红细胞分布宽度变化及意义[J].临床儿科杂志,2020,38(3):182-185.
[13] 王婧,张春霞,雪梅,等.分析超声心动图诊断川崎病冠状动脉Ⅱ、Ⅲ、Ⅳ级损害的相关因素[J].中国临床医学影像杂志,2016,27(12):871-874.
[14] 聂芳,马文涛,徐新.冻干重组人脑利钠肽对老年急性心梗患者Chemerin、Gal-3水平的影响[J].心血管康复医学杂志,2018,27(5):546-550.
[15] 吕元红,王国兵,温鹏强,等.川崎病白细胞介素-4基因组蛋白乙酰化修饰改变及意义[J].中华实用儿科临床杂志,2020,35(6):462-466.
[16] 张静静,罗婧.不同剂量丙种球蛋白治疗小儿川崎病的疗效及对炎症因子和免疫功能的影响[J].临床医学研究与实践,2018,3(30):59-62. |
|
|
|
2022, Vol. 39 
